Cargando…

Belatacept Treatment of Recurrent Late-onset T Cell–mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient

T cell–mediated rejection that appears and persists late after transplantation is often associated with development of de novo donor-specific antibodies. Treatment of this condition often presents a conundrum because of the uncertainty regarding the trade-off between immunosuppression-related toxici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klintmalm, Göran B., Trotter, James F., Demetris, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Liver Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236599/ https://www.ncbi.nlm.nih.gov/pubmed/35774420 http://dx.doi.org/10.1097/TXD.0000000000001076

Ejemplares similares

Acute Antibody-mediated Rejection Coexisting With T Cell–mediated Rejection in Pediatric ABO-incompatible Transplantation
por: Yanagi, Yusuke, et al.
Publicado: (2022)

Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase?
por: Tajima, Tetsuya, et al.
Publicado: (2019)

Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients
por: Engels, Eric A., et al.
Publicado: (2018)

The Role of Dynamic DNA Methylation in Liver Transplant Rejection in Children
por: Ningappa, Mylarappa, et al.
Publicado: (2022)

Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation
por: Parajuli, Sandesh, et al.
Publicado: (2017)

The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients With Biopsy-Proven Acute Rejection Requiring Treatment After Liver Transplantation
por: Goh, Su Kah, et al.
Publicado: (2019)

Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients
por: Jordan, Stanley C., et al.
Publicado: (2018)

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018)

Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein Microarray
por: Okubo, Keita, et al.
Publicado: (2016)

Circulating Donor Heart Exosome Profiling Enables Noninvasive Detection of Antibody-mediated Rejection
por: Hu, Robert W., et al.
Publicado: (2020)

Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection
por: Mező, Blanka, et al.
Publicado: (2019)

Hyperacute Antibody-mediated Rejection Associated With Red Blood Cell Antibodies
por: Shaw, James, et al.
Publicado: (2019)

Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission
por: Mitchell, Robert A., et al.
Publicado: (2018)

Assessment of Carfilzomib Treatment Response in Lung Transplant Recipients With Antibody-mediated Rejection
por: Pham, Christine, et al.
Publicado: (2021)

Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey
por: Akamatsu, Nobuhisa, et al.
Publicado: (2021)

Detailed Analysis of Simultaneous Renal and Liver Allografts in the Presence of DSA
por: O’Leary, Jacqueline G., et al.
Publicado: (2023)

Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients
por: Pottebaum, April A., et al.
Publicado: (2020)

Impact of the Trough Level of Calcineurin Inhibitor on the Prevalence of Donor-Specific Human Leukocyte Antigen Antibodies During Long-Term Follow-Up After Pediatric Liver Transplantation: Antibody Strength and Complement-Binding Ability
por: Tokodai, Kazuaki, et al.
Publicado: (2017)

Polyfunctional donor-reactive T cells are associated with acute T-cell-mediated rejection of the kidney transplant
por: Litjens, Nicolle H R, et al.
Publicado: (2023)

Low Titers of Antidonor ABO Antibodies After ABO-Incompatible Living Donor Liver Transplantation: A Long-Term Follow-Up Study
por: Ueda, Daisuke, et al.
Publicado: (2018)

Antibody-mediated rejection after lung transplantation
por: Bery, Amit I., et al.
Publicado: (2020)

The Role of Complement Split-products as Biomarkers for Acute Antibody-mediated Rejection of Kidney Allografts
por: Abu Jawdeh, Bassam G., et al.
Publicado: (2022)

Very Late Recurrence of Hepatocellular Carcinoma After Orthotopic Liver Transplantation: Presentation and Management
por: Shaw, Brian I., et al.
Publicado: (2019)

Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection
por: Fischman, Clara, et al.
Publicado: (2019)

Class and Kinetics of Weakly Reactive Pretransplant Donor-specific HLA Antibodies Predict Rejection in Kidney Transplant Recipients
por: Morrison, Alexander H., et al.
Publicado: (2019)

Effect of Fc-γ Receptor Polymorphism on Rituximab-Mediated B Cell Depletion in ABO-Incompatible Adult Living Donor Liver Transplantation
por: Sakai, Hiroshi, et al.
Publicado: (2017)

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10
por: Mayer, Katharina A., et al.
Publicado: (2022)

Recurrent Mild Acute Rejections and Donor-specific Antibodies as Risk Factors for Cardiac Allograft Vasculopathy in a National Pediatric Heart Transplant Cohort
por: Kaskinen, Anu K., et al.
Publicado: (2023)

Rituximab Induction to Prevent the Recurrence of PSC After Liver Transplantation—The Lessons Learned From ABO-Incompatible Living Donor Liver Transplantation
por: Yamada, Yohei, et al.
Publicado: (2018)

Donor BMI and Post–living Donor Liver Transplantation Outcomes: A Preliminary Report
por: Lin, Jessica S., et al.
Publicado: (2023)

Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients: Treatment Response Rates and Value of Early Surveillance Biopsies
por: Aziz, Fahad, et al.
Publicado: (2022)

Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection
por: Waiser, Johannes, et al.
Publicado: (2016)

The Kupffer Cell Number Affects the Outcome of Living Donor Liver Transplantation from Elderly Donors
por: Hidaka, Masaaki, et al.
Publicado: (2016)

Rituximab use in late antibody-mediated rejection
por: Bansal, S. B.
Publicado: (2016)

Clinical significance of de novo donor-specific antibody in kidney transplant recipients with chronic antibody-mediated rejection
por: Park, Woo Yeong, et al.
Publicado: (2021)

Liver Transplantation With Grafts From Super Obese Donors
por: Vargas, Paola A., et al.
Publicado: (2021)

A Donor Age-Based and Graft Volume–Based Analysis for Living Donor Liver Transplantation in Elderly Recipients
por: Imamura, Hajime, et al.
Publicado: (2017)

The Trend of Serum Creatinine Does Not Predict Follow-Up Biopsy Findings Among Kidney Transplant Recipients With Antibody-Mediated Rejection
por: Parajuli, Sandesh, et al.
Publicado: (2023)

Kidney Donor Profile Index Is a Reliable Alternative to Liver Donor Risk Index in Quantifying Graft Quality in Liver Transplantation
por: Scheuermann, Uwe, et al.
Publicado: (2019)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f3f9kt7pj22hhstpbgn9mgoa02